Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07080242 · ClinicalTrials.gov registry record · Phase 1
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
A Phase 1 study of Small Cell Lung Cancer Metastatic or Locally Advanced and Neuroendocrine Cancer, sponsored by SystImmune.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT07080242 is a Phase 1 study of Small Cell Lung Cancer Metastatic or Locally Advanced and Neuroendocrine Cancer that is actively recruiting participants, run by SystImmune. The registered enrollment target is 120 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT07080242, a Phase 1 study of Small Cell Lung Cancer Metastatic or Locally Advanced and Neuroendocrine Cancer, is actively recruiting participants, sponsored by SystImmune.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
Conditions Studied
Interventions
- DRUG BL-M14D1
Study Locations (20)
Texas
- NEXT Dallas - Dallas
- START Dallas- Fort Worth - Dallas
- MD Anderson Cancer Center - Houston
- NEXT Houston - Houston
- START- San Antonio - San Antonio
California
- Valkyrie Clinical Trials - Los Angeles
- UCLA - Los Angeles
- UCSF- San Francisco (Helen Diller Family Comprehensive Cancer Center) - San Francisco
New Jersey
- John Theurer Cancer Center-Hackensack - Hackensack
- Rutgers Cancer Institute - New Brunswick
Colorado
- University of Colorado - Anschutz Cancer Pavilion - Aurora
Connecticut
- Yale Cancer Center - New Haven
Georgia
- Emory Winship - Atlanta
Kentucky
- University of Kentucky - Markey Cancer Center - Lexington
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07080242
The ClinicalTrials.gov registry entry for NCT07080242 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SystImmune, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Small Cell Lung Cancer Metastatic or Locally Advanced appearing as the primary indexed condition, and to 1 intervention - of which BL-M14D1 is the first listed.
NCT07080242 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Texas, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT07080242 about?
NCT07080242 is a clinical study titled "Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors". The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
What is the current status of trial NCT07080242?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2025-04-28. Estimated completion is 2027-12-31.
What conditions does trial NCT07080242 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic or Locally Advanced Neuroendocrine Prostate Cancer, Metastatic or Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma, Metastatic or Locally Advanced Merkel Cell Carcinoma.
What interventions are being tested in trial NCT07080242?
The interventions under investigation include: BL-M14D1 (DRUG).
Who is sponsoring clinical trial NCT07080242?
This trial is sponsored by SystImmune, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07080242 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Small Cell Lung Cancer Metastatic or Locally Advanced
All registered trials for this condition
Neuroendocrine Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.